A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy

CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS

NCT04287309 ·Status: UNKNOWN

Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies

NCT05895994 ·Status: COMPLETED ·Phase: EARLY_PHASE1

CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma

NCT03488160 ·Status: UNKNOWN ·Phase: NA

A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies

NCT04011293 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

NCT04626908 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

PD1-CD19-CART in Patients With r/r B-cell Lymphoma

NCT04213469 ·Status: COMPLETED ·Phase: NA

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

NCT04648475 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

NCT04271800 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

NCT03881761 ·Status: UNKNOWN ·Phase: PHASE1

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

NCT03994913 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies

NCT05015972 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

NCT05651100 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

NCT04271410 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

NCT04196205 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Safety and Efficacy Evaluation of CD19-UCART

NCT03229876 ·Status: SUSPENDED ·Phase: NA

A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms

NCT07200479 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL

NCT05716113 ·Status: COMPLETED ·Phase: EARLY_PHASE1

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

NCT04690192 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma

NCT04169932 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

NCT05105867 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma

NCT04232826 ·Status: COMPLETED ·Phase: PHASE1

A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT07068906 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1

Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia

NCT02810223 ·Status: UNKNOWN ·Phase: PHASE1

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

NCT05436223 ·Status: RECRUITING ·Phase: PHASE2

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

NCT04532268 ·Status: RECRUITING ·Phase: EARLY_PHASE1